AHSCT is an intensive treatment which carries a very high risk of infection for many weeks, due to severe immunosuppression as part of the treatment pathway. In March 2020 the Association of British Neurologists (ABN) recommended postponing this treatment in patients with MS until the risk of coronavirus receded, due to the potential for severe illness in t...